Cargando…
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotox...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508996/ https://www.ncbi.nlm.nih.gov/pubmed/36164415 http://dx.doi.org/10.2147/DDDT.S377697 |